scorecardresearch
Follow Us:
Sunday, October 24, 2021

AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

The drug, called AZD7442, reduced the risk of developing severe Covid-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial.

By: Reuters |
Updated: October 11, 2021 6:49:29 pm
AstraZeneca is also developing the drug cocktail as a therapy to protect people who do not have a strong enough immune response to Covid-19 vaccines.

AstraZeneca’s experimental Covid-19 antibody-drug cocktail succeeded in reducing severe disease or death in non-hospitalised patients in a late-stage study, the British drugmaker said on Monday.

The drug, called AZD7442, reduced the risk of developing severe Covid-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial.

[oovvuu-embed id=”ee1f3676-9834-4564-b8d3-6d54d3d3cd76″]

“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.

The company will discuss the data with health authorities, it added, without elaborating.

AstraZeneca is also developing the drug cocktail as a therapy to protect people who do not have a strong enough immune response to Covid-19 vaccines. It requested emergency approval from US regulators for its use as a prevention drug last week.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement